Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1 Dose Escalation and Expansion Study of EO-3021, an Anti-claudin 18.2 (CLDN18.2) Antibody Drug Conjugate, in Patients With Solid Tumors Likely to Express CLDN18.2

NCT05980416 is registered in ClinicalTrials.gov with Elevation Oncology as lead sponsor.

NCT NCT05980416
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05980416 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1 Dose Escalation and Expansion Study of EO-3021, an Anti-claudin 18.2 (CLDN18.2) Antibody Drug Conjugate, in Patients With Solid Tumors Likely to Express CLDN18.2
Lead sponsor
Elevation Oncology
Phase
Phase 1
Overall status
Terminated
Start date
August 10, 2023
Completion date
June 2, 2025
Enrollment
88 (actual)
Sites
20

Conditions

As the registry lists them; a condition with its own page is linked.

digestive system neoplasm, gastrointestinal neoplasms, neoplasms, neoplasms by site, stomach neoplasm